Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.
Official title: A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-08-05
Completion Date
2027-09
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
LY4256984
Administered IT
Placebo
Administered IT
Locations (12)
UZ Leuven
Leuven, Belgium
Heritage Medical Research Clinic
Calgary, Canada
Walter Mackenzie Health Sciences Centre
Edmonton, Canada
London Health Sciences Centre
London, Canada
Montreal Neurological Institute and Hospital
Montreal, Canada
Sunnybrook Research Institute
Toronto, Canada
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Universitätsmedizin Rostock Sektion für Translationale Neurodegeneration "Albrecht Kossel" Klinik und Poliklinik für Neurologie
Rostock, Germany
Universitätsklinikum Ulm
Ulm, Germany
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain